Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT05040971
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide 2.4 mg — DRUG
    Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg
  • Placebo — DRUG
    Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week

Study Details

This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes. This study will look at how much weight participants lose, and if participants can go from having blood sugar that is higher than normal (prediabetes) to having normal blood sugar. Semaglutide is compared to a "dummy" medicine. The "dummy" medicine looks like semaglutide but has no effect on the body. In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment they get is decided by chance. Participants are 2 times as likely to get semaglutide as "dummy" medicine. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 19 months. Participants have to take the study medicine every week for the first 12 months. The last 7 months participants will not take any medication. Participants will have 14 clinic visits and 1 phone call with the study staff. At 9 of the clinic visits Participants will have blood samples taken. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Key Dates

Start date
Sep 6, 2021
Status verified
Jan 2026
Primary completion
Jan 6, 2023
Completion
Jul 14, 2023

Study Design

Enrollment
207 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide
    Participants will receive subcutaneus (s.c.) semaglutide 2.4 mg once weekly for 52 weeks
  • Placebo Comparator: Placebo (semaglutide)
    Participants will receive subcutaneus (s.c.) placebo (semaglutide) once weekly for 52 weeks

Primary Outcome Measure

Change in Body Weight (Percentage [%]) [ Time Frame: From randomisation (week 0) to end of treatment (week 52) ]

Related Studies